Skip to main content
Top
Published in: BMC Geriatrics 1/2022

Open Access 01-12-2022 | Stroke | Research

Association between early detected heart failure stages and future cardiovascular and non-cardiovascular events in the elderly (Copenhagen Heart Failure Risk Study)

Authors: Saaima Parveen, Bochra Zareini, Anojhaan Arulmurugananthavadivel, Caroline Kistorp, Jens Faber, Lars Køber, Christian Hassager, Tor Biering Sørensen, Charlotte Andersson, Deewa Zahir, Kasper Iversen, Emil Wolsk, Gunnar Gislason, Freja Gaborit, Morten Schou

Published in: BMC Geriatrics | Issue 1/2022

Login to get access

Abstract

Background

Early stages of heart failure (HF) are associated with an increased risk of hospitalization and increased mortality, however the course of progression and the impact of non-cardiovascular comorbidities on adverse events in elderly high-risk patients are unknown.

Aim

To examine the risk of future cardiovascular (CV) and non-CV events in early stages of HF in a cohort of elderly patients (age ≥ 60 with ≥ 1 risk factor for HF and without known or clinically suspected HF).

Methods

A total of 400 patients (American Heart Association HF stage A: N = 177; stage B: N = 150; stage C: N = 73) from the Copenhagen Heart Failure Risk Study were identified and followed for the main composite outcome of a HF hospitalization (HFH), ischemic heart disease (IHD), stroke, and all-cause death, recorded within the Danish nationwide registries. Non-CV hospitalization was a secondary outcome. Absolute risk was calculated by the Aalen-Johansen estimator.

Results

The median follow-up time was 3.3 years, total number of events were 83, and the 3-year risk (95% confidence interval) of the main outcome was 12.8% (7.8–17.9), 22.8% (16.1–29.6) and 31.8% (21.0–42.6) for patients with stage A, B, and C, respectively. 1.1% (0.0–2.7), 3.4% (1.0–6.3) and 10.0% (2.8–16.3) experienced HFH as their first event, whereas 37.3% (30.2–44.4), 49.7% (41.6–57.8) and 54.8% (43.4–66.2) were admitted for non-CV causes as their first event.

Conclusion

The risk of HFH, IHD, stroke and all-cause death increased with severity of HF stage, and 10% of patients with undiagnosed HF stage C were admitted for HF within 3 years. However, the risk of non-CV hospitalizations was greater compared to the risk of experiencing HFH.
Appendix
Available only for authorised users
Literature
1.
go back to reference Xanthakis V, Enserro DM, Larson MG, Wollert KC, Januzzi JL, Levy D, et al. Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. JACC Heart Failure. 2016;4:808–15.CrossRef Xanthakis V, Enserro DM, Larson MG, Wollert KC, Januzzi JL, Levy D, et al. Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. JACC Heart Failure. 2016;4:808–15.CrossRef
2.
go back to reference Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC, et al. Prevalence and prognostic significance of heart failure stages: Application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation. 2007;115:1563–70.CrossRef Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC, et al. Prevalence and prognostic significance of heart failure stages: Application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation. 2007;115:1563–70.CrossRef
3.
go back to reference Shah AM, Claggett B, Loehr LR, Chang PP, Matsushita K, Kitzman D, et al. Heart Failure Stages among Older Adults in the Community: The Atherosclerosis Risk in Communities Study. Circulation. 2017;135:224–40.CrossRef Shah AM, Claggett B, Loehr LR, Chang PP, Matsushita K, Kitzman D, et al. Heart Failure Stages among Older Adults in the Community: The Atherosclerosis Risk in Communities Study. Circulation. 2017;135:224–40.CrossRef
4.
go back to reference Gaborit FS, Kistorp C, Kümler T, Hassager C, Tønder N, Køber L, et al. Prevalence of early stages of heart failure in an elderly risk population: The Copenhagen Heart Failure Risk Study. Open Heart. 2019;6. Gaborit FS, Kistorp C, Kümler T, Hassager C, Tønder N, Køber L, et al. Prevalence of early stages of heart failure in an elderly risk population: The Copenhagen Heart Failure Risk Study. Open Heart. 2019;6.
5.
go back to reference Wolsk E, Claggett B, Køber L, Pocock S, Yusuf S, Swedberg K, et al. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. Eur J Heart Fail. 2018;20:504–10.CrossRef Wolsk E, Claggett B, Køber L, Pocock S, Yusuf S, Swedberg K, et al. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. Eur J Heart Fail. 2018;20:504–10.CrossRef
6.
go back to reference Solomon SD, Vaduganathan M, L Claggett B, Packer M, Zile M, Swedberg K, et al. Sacubitril/Valsartan across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020;141:352–61. Solomon SD, Vaduganathan M, L Claggett B, Packer M, Zile M, Swedberg K, et al. Sacubitril/Valsartan across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020;141:352–61.
7.
go back to reference Baumgartner H, de Backer J, Babu-Narayan S, v, Budts W, Chessa M, Diller G-P, et al. ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2020;2020(42):563–645. Baumgartner H, de Backer J, Babu-Narayan S, v, Budts W, Chessa M, Diller G-P, et al. ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2020;2020(42):563–645.
8.
go back to reference Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–20.CrossRef Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–20.CrossRef
9.
go back to reference Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2005;112:e156-215. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2005;112:e156-215.
10.
go back to reference Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.CrossRef Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.CrossRef
11.
go back to reference Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–71.CrossRef Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–71.CrossRef
12.
go back to reference Kümler T, Gislason GH, Kirk V, Bay M, Nielsen OW, Køber L, et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail. 2008;10:658–60.CrossRef Kümler T, Gislason GH, Kirk V, Bay M, Nielsen OW, Køber L, et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail. 2008;10:658–60.CrossRef
13.
go back to reference Adelborg K, Sundbøll J, Munch T, Frøslev T, Sørensen HT, Bøtker HE, et al. Positive predictive value of cardiac examination, procedure and surgery codes in the Danish National Patient Registry: A population-based validation study. BMJ Open. 2016;6:1–6.CrossRef Adelborg K, Sundbøll J, Munch T, Frøslev T, Sørensen HT, Bøtker HE, et al. Positive predictive value of cardiac examination, procedure and surgery codes in the Danish National Patient Registry: A population-based validation study. BMJ Open. 2016;6:1–6.CrossRef
14.
go back to reference Sundbøll J, Adelborg K, Munch T, Frøslev T, Sørensen HT, Bøtker HE, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: A validation study. BMJ Open. 2016;6. Sundbøll J, Adelborg K, Munch T, Frøslev T, Sørensen HT, Bøtker HE, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: A validation study. BMJ Open. 2016;6.
15.
go back to reference Pocock SJ, Ariti CA, McMurray JJV, Maggioni A, Køber L, Squire IB, et al. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34:1404–13.CrossRef Pocock SJ, Ariti CA, McMurray JJV, Maggioni A, Køber L, Squire IB, et al. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34:1404–13.CrossRef
16.
18.
go back to reference Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226–33.CrossRef Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226–33.CrossRef
19.
go back to reference Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005.CrossRef Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005.CrossRef
20.
go back to reference Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;271:132–9.CrossRef Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;271:132–9.CrossRef
21.
go back to reference Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New Engl J Med 2021;385:1–11. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New Engl J Med 2021;385:1–11.
22.
go back to reference Morbach C, Gelbrich G, Tiffe T, Eichner FA, Christa M, Mattern R, et al. Prevalence and determinants of the precursor stages of heart failure : results from the population-based STAAB cohort study. 2021:924–34. Morbach C, Gelbrich G, Tiffe T, Eichner FA, Christa M, Mattern R, et al. Prevalence and determinants of the precursor stages of heart failure : results from the population-based STAAB cohort study. 2021:924–34.
23.
go back to reference Göbel S, Prochaska JH, Tröbs SO, Panova-Noeva M, Espinola-Klein C, Michal M, et al. Rationale, design and baseline characteristics of the MyoVasc study: A prospective cohort study investigating development and progression of heart failure. 2021;28:1009–18. Göbel S, Prochaska JH, Tröbs SO, Panova-Noeva M, Espinola-Klein C, Michal M, et al. Rationale, design and baseline characteristics of the MyoVasc study: A prospective cohort study investigating development and progression of heart failure. 2021;28:1009–18.
24.
go back to reference Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–9.CrossRef Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–9.CrossRef
25.
go back to reference Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National patient registry: A review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90.CrossRef Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National patient registry: A review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90.CrossRef
Metadata
Title
Association between early detected heart failure stages and future cardiovascular and non-cardiovascular events in the elderly (Copenhagen Heart Failure Risk Study)
Authors
Saaima Parveen
Bochra Zareini
Anojhaan Arulmurugananthavadivel
Caroline Kistorp
Jens Faber
Lars Køber
Christian Hassager
Tor Biering Sørensen
Charlotte Andersson
Deewa Zahir
Kasper Iversen
Emil Wolsk
Gunnar Gislason
Freja Gaborit
Morten Schou
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2022
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-022-02875-1

Other articles of this Issue 1/2022

BMC Geriatrics 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine